Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines

Anti-Cancer Drugs

Volumn 13, Issue 3, 2002, Pages 245-254

  Heikkilä, Pia ^a,f   Teronen, Olli ^a,d,e   Moilanen, Merja ^c   Konttinen, Yrjö T ^a   Hanemaaijer, Roeland ^b   Laitinen, Minna ^e   Maisi, Päivi ^f   Van Der Pluijm, Gabri ^g   Bartlett, John D ^h   Salo, Tuula ^c   Sorsa, Timo ^a,f  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TNO   (Netherlands)

^c UNIVERSITY OF OULU   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h FORSYTH INSTITUTE   (United States)

Author keywords

Bisphosphonates; Inhibition; Invasion; Matrix metalloproteinases; Migration

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGENASE 3; CYSTEINYLTHREONYLTHREONYLHISTIDYLTRYPTOPHYLGLYCYLPHENYLALANYLTHREONYLLEUCYL CYSTEINE; ENAMELYSIN; FIBRONECTIN; GELATINASE INHIBITOR; MACROPHAGE ELASTASE; MATRIGEL; MATRIX METALLOPROTEINASE; PAMIDRONIC ACID; SERINE PROTEINASE; STROMELYSIN; UNCLASSIFIED DRUG; UROKINASE; ZOLEDRONIC ACID;

ARTICLE; CANCER CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CHELATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FIBROSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL ADHESION; CELL MOVEMENT; CELL SURVIVAL; COLLAGEN; COLLAGENASES; DIPHOSPHONATES; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FIBRONECTINS; HUMANS; LAMININ; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; PROTEOGLYCANS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036250129     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200203000-00006     Document Type: Article

References (41)

1. Bisphosphonates spearhead new approach to treating bone metastases
2. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
3. Bisphosphonates in the treatment of bone diseases
4. Breast cancer and osteolytic metastases: Can bisphosphonates help?
5. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
6. Bisphosphonates: Mechanisms of action
7. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate)
8. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate
9. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: Localization in the pannus hard tissue junction and inhibition by alendronate
10. Alendronate blocks metalloproteinase secretion and bone collagen 1 release by PC-3 ML cells in SCID mice
11. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
12. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells
13. Matrix metalloproteinases in tumor invasion
14. Plasminogen activators and matrix metalloproteinases in angiogenesis
15. Activation of type IV procollagenases by human tumor-associated trypsin-2
16. Identification and structural and functional characterization of human enamelysin (MMP-20)
17. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: Association with reduced cancer cell migration
18. Modified proentzymes as artifcial substrates for proteolytic enzymes: Colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase
19. The effects of chemically modified tetracyclines (CMTs) on human keratinocyte proliferation and migration
20. 1 integrins during human melanoma cell invasion
21. Tumor targeting with a selective gelatinase inhibitor
22. Inhibition of osteolytic bone metastasis of breast cancer by combinated treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
23. CMT/Clodronate combination therapy synergistically inhibits alveolar bone loss in LPS-induced periodontitis
24. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
25. Molecular cloning and expression of collagenase-3 a novel human matrix metalloproteinase produced by breast carcinomas
26. Biochemical characterization of human collagenase-3
27. Stromelysin-3 expression promotes tumor burden in nude mice
28. MMP-12. A proteinase that is indispensible for macrophage invasion is highly expressed in osteoclasts
29. Expression and regulation of MMP-20 in human tongue carcinoma cells
30. Bisphosphonates inhibit breast and prostate carcinoma cell invasion an early event in the formation of bone metastases
31. Functional sites of chemically modified tetracyclines: Inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases
32. In vitro sensitivity of three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation
33. Changing view of the role of matrix metalloproteinases in metastasis
34. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and bisphosphonate alendronate
35. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemia and metastatic bone diseases
36. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
37. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
38. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
39. Bisphosphonates as anticancer drugs
40. A combination of a chemically-modified doxyxycline and a bisphosphonate synergistically inhibits LPS-induced periodontal breakdown in rats
41. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast cancer to bone